International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic...

Area of Science:

• Cardiovascular Pharmacology
• Stem Cell Biology
• Drug Safety Assessment

Background:

• Assessing drug-induced proarrhythmia is crucial for cardiac safety.
• Existing in vitro models have limitations in predicting torsades de pointes (TdP) risk.
• Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer a promising alternative.

Purpose of the Study:

• To evaluate the utility of hiPSC-CMs as an in vitro proarrhythmia model.
• To assess concentration dependence and variability in hiPSC-CM electrophysiologic responses to known proarrhythmic drugs.
• To determine if hiPSC-CMs can accurately categorize drugs based on TdP risk.

Main Methods:

• A blinded, multisite study using two commercial hiPSC-CM lines.
• Evaluation of 28 drugs with known TdP risk categories.
• Utilized multielectrode array and voltage-sensing optical mapping techniques.
• Statistical modeling (logistic and ordinal linear regression) to correlate drug responses with TdP risk.

Main Results:

• Three key predictors (arrhythmia events, repolarization prolongation) accurately categorized drug TdP risk (AUC ~0.8).
• hiPSC-CM line, testing site, and platform had minimal impact on drug categorization.
• Demonstrated concentration-dependent electrophysiologic responses to tested drugs.

Conclusions:

• hiPSC-CMs are a valuable tool for detecting drug-induced proarrhythmic effects.
• This model shows utility within the Comprehensive In Vitro Proarrhythmia Assay framework.
• The approach offers a reliable and reproducible method for early-stage drug safety screening.